$92.03M Market Cap.
HBIO Market Cap. (MRY)
HBIO Shares Outstanding (MRY)
HBIO Assets (MRY)
Total Assets
$126.64M
Total Liabilities
$63.30M
Total Investments
$0
HBIO Income (MRY)
Revenue
$94.14M
Net Income
-$12.40M
Operating Expense
$60.98M
HBIO Cash Flow (MRY)
CF Operations
$1.44M
CF Investing
-$1.34M
CF Financing
-$131.00K
HBIO Dividends (MRY)
Period | Dividends | Yield % | Growth % | Payout Ratio | Coverage Ratio |
|---|---|---|---|---|---|
2024 | $0 | 0% | 0% | 0% | - |
2023 | $0 | 0% | 0% | 0% | - |
2022 | $0 | 0% | 0% | 0% | - |
2021 | $0 | 0% | 0% | 0% | - |
2020 | $0 | 0% | - | 0% | - |
HBIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $126,644,000 (-7.81%) | $137,366,000 (-5.50%) | $145,360,000 (-10.46%) | $162,344,000 (3.90%) |
Assets Current | $45,117,000 (-8.00%) | $49,038,000 (-4.08%) | $51,124,000 (-16.98%) | $61,583,000 (19.12%) |
Assets Non-Current | $81,527,000 (-7.70%) | $88,328,000 (-6.27%) | $94,236,000 (-6.48%) | $100,761,000 (-3.63%) |
Goodwill & Intangible Assets | $67,456,000 (-7.72%) | $73,101,000 (-5.40%) | $77,274,000 (-9.17%) | $85,074,000 (-7.27%) |
Shareholders Equity | $63,340,000 (-13.32%) | $73,074,000 (1.18%) | $72,220,000 (-13.41%) | $83,401,000 (8.76%) |
Property Plant & Equipment Net | $11,238,000 (28.38%) | $8,754,000 (-4.66%) | $9,182,000 (-10.96%) | $10,312,000 (-12.02%) |
Cash & Equivalents | $4,108,000 (-4.09%) | $4,283,000 (-4.99%) | $4,508,000 (-42.36%) | $7,821,000 (-5.96%) |
Accumulated Other Comprehensive Income | -$15,670,000 (-10.43%) | -$14,190,000 (5.73%) | -$15,052,000 (-50.11%) | -$10,027,000 (23.26%) |
Deferred Revenue | $3,806,000 (-15.57%) | $4,508,000 (33.77%) | $3,370,000 (-21.00%) | $4,266,000 (13.13%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $23,245,000 (-5.95%) | $24,716,000 (-6.52%) | $26,439,000 (-4.16%) | $27,587,000 (23.92%) |
Trade & Non-Trade Receivables | $14,866,000 (-7.66%) | $16,099,000 (-3.63%) | $16,705,000 (-23.49%) | $21,834,000 (22.90%) |
Trade & Non-Trade Payables | $4,787,000 (-13.81%) | $5,554,000 (-13.85%) | $6,447,000 (31.28%) | $4,911,000 (-17.77%) |
Accumulated Retained Earnings (Deficit) | -$158,010,000 (-8.52%) | -$145,605,000 (-2.40%) | -$142,190,000 (-7.17%) | -$132,674,000 (-0.22%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $710,000 (-8.51%) | $776,000 (31.53%) | $590,000 (-62.13%) | $1,558,000 (-17.96%) |
Total Debt | $43,337,000 (1.32%) | $42,773,000 (-21.14%) | $54,241,000 (-4.77%) | $56,960,000 (-1.11%) |
Debt Current | $36,956,000 (407.99%) | $7,275,000 (22.35%) | $5,946,000 (10.58%) | $5,377,000 (40.32%) |
Debt Non-Current | $6,381,000 (-82.02%) | $35,498,000 (-26.50%) | $48,295,000 (-6.37%) | $51,583,000 (-4.06%) |
Total Liabilities | $63,304,000 (-1.54%) | $64,292,000 (-12.10%) | $73,140,000 (-7.35%) | $78,943,000 (-0.79%) |
Liabilities Current | $54,958,000 (107.06%) | $26,542,000 (14.16%) | $23,249,000 (-8.16%) | $25,316,000 (20.25%) |
Liabilities Non-Current | $8,346,000 (-77.89%) | $37,750,000 (-24.34%) | $49,891,000 (-6.97%) | $53,627,000 (-8.36%) |
HBIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $94,135,000 (-16.14%) | $112,250,000 (-0.96%) | $113,335,000 (-4.68%) | $118,904,000 (16.46%) |
Cost of Revenue | $39,369,000 (-14.75%) | $46,179,000 (-12.07%) | $52,516,000 (2.47%) | $51,252,000 (16.33%) |
Selling General & Administrative Expense | $43,705,000 (-6.79%) | $46,888,000 (-5.34%) | $49,534,000 (1.20%) | $48,947,000 (12.72%) |
Research & Development Expense | $10,406,000 (-11.54%) | $11,764,000 (-4.58%) | $12,329,000 (14.17%) | $10,799,000 (24.34%) |
Operating Expenses | $60,977,000 (-4.99%) | $64,177,000 (-5.28%) | $67,752,000 (3.30%) | $65,586,000 (13.43%) |
Interest Expense | $3,209,000 (-10.64%) | $3,591,000 (40.93%) | $2,548,000 (65.45%) | $1,540,000 (-68.12%) |
Income Tax Expense | $740,000 (-13.85%) | $859,000 (154.90%) | $337,000 (127.70%) | $148,000 (-71.43%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$12,405,000 (-263.25%) | -$3,415,000 (64.11%) | -$9,516,000 (-3204.17%) | -$288,000 (96.31%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$12,405,000 (-263.25%) | -$3,415,000 (64.11%) | -$9,516,000 (-3204.17%) | -$288,000 (96.31%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$12,405,000 (-263.25%) | -$3,415,000 (64.11%) | -$9,516,000 (-3204.17%) | -$288,000 (96.31%) |
Weighted Average Shares | $43,538,000 (2.64%) | $42,420,000 (2.43%) | $41,413,000 (2.65%) | $40,343,000 (4.41%) |
Weighted Average Shares Diluted | $43,538,000 (2.64%) | $42,420,000 (2.43%) | $41,413,000 (2.65%) | $40,343,000 (4.41%) |
Earning Before Interest & Taxes (EBIT) | -$8,456,000 (-917.00%) | $1,035,000 (115.61%) | -$6,631,000 (-573.64%) | $1,400,000 (156.89%) |
Gross Profit | $54,766,000 (-17.11%) | $66,071,000 (8.64%) | $60,819,000 (-10.10%) | $67,652,000 (16.56%) |
Operating Income | -$6,211,000 (-427.93%) | $1,894,000 (127.32%) | -$6,933,000 (-435.58%) | $2,066,000 (834.84%) |
HBIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$1,344,000 (25.29%) | -$1,799,000 (-13.14%) | -$1,590,000 (-18.22%) | -$1,345,000 (4.07%) |
Net Cash Flow from Financing | -$131,000 (98.92%) | -$12,134,000 (-327.71%) | -$2,837,000 (-1025.79%) | -$252,000 (96.84%) |
Net Cash Flow from Operations | $1,440,000 (-89.73%) | $14,028,000 (1117.71%) | $1,152,000 (-8.72%) | $1,262,000 (-86.48%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$175,000 (22.22%) | -$225,000 (93.21%) | -$3,313,000 (-567.94%) | -$496,000 (-2655.56%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $512,000 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $1,919,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | -$3,263,000 (-41.19%) | -$2,311,000 (-45.35%) | -$1,590,000 (-18.22%) | -$1,345,000 (4.07%) |
Issuance (Repayment) of Debt Securities | $66,000 (100.63%) | -$10,541,000 (-490.20%) | -$1,786,000 (-3334.62%) | -$52,000 (99.31%) |
Issuance (Purchase) of Equity Shares | $380,000 (-59.14%) | $930,000 (61.18%) | $577,000 (-82.59%) | $3,314,000 (395.37%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | -$140,000 (56.25%) | -$320,000 (-742.11%) | -$38,000 (76.40%) | -$161,000 (-905.00%) |
Share Based Compensation | $4,340,000 (-13.20%) | $5,000,000 (13.35%) | $4,411,000 (5.80%) | $4,169,000 (14.31%) |
Depreciation Amortization & Accretion | $7,157,000 (2.27%) | $6,998,000 (-7.62%) | $7,575,000 (-0.60%) | $7,621,000 (-0.14%) |
HBIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 58.20% (-1.19%) | 58.90% (9.68%) | 53.70% (-5.62%) | 56.90% (0.18%) |
Profit Margin | -13.20% (-340.00%) | -3.00% (64.29%) | -8.40% (-4100.00%) | -0.20% (97.37%) |
EBITDA Margin | -1.40% (-119.44%) | 7.20% (800.00%) | 0.80% (-89.47%) | 7.60% (49.02%) |
Return on Average Equity (ROAE) | -18.70% (-306.52%) | -4.60% (64.06%) | -12.80% (-3100.00%) | -0.40% (96.08%) |
Return on Average Assets (ROAA) | -9.50% (-295.83%) | -2.40% (61.90%) | -6.30% (-3050.00%) | -0.20% (96.08%) |
Return on Sales (ROS) | -9.00% (-1100.00%) | 0.90% (115.25%) | -5.90% (-591.67%) | 1.20% (150.00%) |
Return on Invested Capital (ROIC) | -12.60% (-1150.00%) | 1.20% (117.91%) | -6.70% (-546.67%) | 1.50% (155.56%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -7.54 (88.73%) | -66.88 (-455.30%) | -12.04 (98.29%) | -705 (-3186.71%) |
Price to Sales Ratio (P/S) | 0.98 (-51.73%) | 2.02 (99.80%) | 1.01 (-57.69%) | 2.39 (47.29%) |
Price to Book Ratio (P/B) | 1.45 (-53.50%) | 3.13 (95.56%) | 1.6 (-53.68%) | 3.45 (58.18%) |
Debt to Equity Ratio (D/E) | 1 (13.52%) | 0.88 (-13.13%) | 1.01 (6.97%) | 0.95 (-8.77%) |
Earnings Per Share (EPS) | -0.28 (-250.00%) | -0.08 (65.22%) | -0.23 (-2200.00%) | -0.01 (95.00%) |
Sales Per Share (SPS) | 2.16 (-18.29%) | 2.65 (-3.32%) | 2.74 (-7.13%) | 2.95 (11.54%) |
Free Cash Flow Per Share (FCFPS) | -0.04 (-115.22%) | 0.28 (2609.09%) | -0.01 (-450.00%) | -0 (-100.98%) |
Book Value Per Share (BVPS) | 1.46 (-15.55%) | 1.72 (-1.20%) | 1.74 (-15.63%) | 2.07 (4.18%) |
Tangible Assets Book Value Per Share (TABVPS) | 1.36 (-10.30%) | 1.51 (-7.85%) | 1.64 (-14.15%) | 1.92 (14.67%) |
Enterprise Value Over EBIT (EV/EBIT) | -16 (-106.18%) | 259 (1136.00%) | -25 (-110.42%) | 240 (372.73%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -101.64 (-404.28%) | 33.4 (-81.14%) | 177.08 (375.11%) | 37.27 (-11.49%) |
Asset Turnover | 0.72 (-8.82%) | 0.79 (6.15%) | 0.75 (-2.22%) | 0.77 (14.86%) |
Current Ratio | 0.82 (-55.57%) | 1.85 (-15.96%) | 2.2 (-9.62%) | 2.43 (-0.94%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$1,823,000 (-115.56%) | $11,717,000 (2775.11%) | -$438,000 (-427.71%) | -$83,000 (-101.05%) |
Enterprise Value (EV) | $132,026,070 (-50.80%) | $268,328,116 (60.52%) | $167,161,796 (-50.28%) | $336,219,131 (54.40%) |
Earnings Before Tax (EBT) | -$11,665,000 (-356.38%) | -$2,556,000 (72.15%) | -$9,179,000 (-6456.43%) | -$140,000 (98.08%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$1,299,000 (-116.17%) | $8,033,000 (750.95%) | $944,000 (-89.54%) | $9,021,000 (74.45%) |
Invested Capital | $43,459,000 (-42.98%) | $76,213,000 (-19.41%) | $94,570,000 (-6.45%) | $101,093,000 (9.00%) |
Working Capital | -$9,841,000 (-143.75%) | $22,496,000 (-19.30%) | $27,875,000 (-23.14%) | $36,267,000 (18.34%) |
Tangible Asset Value | $59,188,000 (-7.90%) | $64,265,000 (-5.61%) | $68,086,000 (-11.89%) | $77,270,000 (19.77%) |
Market Capitalization | $92,031,070 (-59.70%) | $228,382,116 (97.92%) | $115,391,796 (-59.89%) | $287,714,131 (72.07%) |
Average Equity | $66,180,250 (-10.89%) | $74,272,000 (-0.33%) | $74,519,500 (-5.70%) | $79,026,000 (3.33%) |
Average Assets | $129,989,000 (-8.07%) | $141,394,500 (-6.62%) | $151,422,500 (-2.53%) | $155,359,000 (1.41%) |
Invested Capital Average | $66,986,500 (-21.31%) | $85,128,250 (-14.38%) | $99,427,500 (8.03%) | $92,034,750 (2.53%) |
Shares | 43,616,621 (2.17%) | 42,688,246 (2.47%) | 41,657,688 (2.08%) | 40,810,515 (4.71%) |
